<DOC>
	<DOC>NCT02284607</DOC>
	<brief_summary>This Phase 1, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of two, single intravenous (IV) high doses of MHAA4549A as compared to placebo when administered to healthy volunteers.</brief_summary>
	<brief_title>A Study of High Dose MHAA4549A in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Age 18 years and older Body mass index (BMI) between 18 and 32 kg/m2, inclusive Weight 40 100 kg In good health, determined by no clinically significant findings from medical history, 12lead ECG, vital signs, and clinical laboratory evaluations Willing to use acceptable contraceptive measures as defined by the protocol Agreeable to, and deemed able to by the investigator, to comply with the requirements of the study, including the followup period Willing to abstain from the use of drugs of abuse while enrolled in the study History or clinically significant manifestations of disorders History of acute allergic reaction or drug allergies History or presence of an abnormal ECG History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit History of significant drug abuse within 1 year prior to screening Current tobacco smokers Positive drug screen at screening or at checkin Positive pregnancy test result at screening or Day 1 or breast feeding during the study Males who have a pregnant female partner Donation of plasma within 7 days prior to study drug administration Donation or loss of whole blood Receipt of blood products within 2 months before initiation of dosing on Day 1 History of malignancy within 10 years of screening except completely excised basal cell carcinoma or squamous cell carcinoma of the skin History of severe systemic bacterial, fungal, or parasitic infections associated with more than two hospitalizations per year or more than two courses of intravenous (IV) antibiotics within 1 year Received oral antibiotics within 4 weeks before initiation of dosing on Day 1, or IV antibiotics within 8 weeks before initiation of dosing Hospitalization within 4 weeks before initiation of dosing on Day 1 Use of any over the counter or prescription medications/products within 7 days prior to Day 1 and unwilling to abstain from the use of such drugs up until at least the Day 29 study visit, unless deemed acceptable by the investigator and Sponsor Participation in a clinical trial within 4 weeks Received any vaccine within 14 days prior to screening Positive blood test for chronic viral infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>